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Aims: Previous investigations by our group have shown that prenatal exposure to lipopolysaccharide (LPS),
which mimics infections by Gram-negative bacteria, induced autistic-like behavior. No effective treatment yet
exists for autism. Therefore, we used our rat model to test a possible treatment for autism. We selected zinc as
the prenatal treatment to prevent or ease the impairments induced by LPS because LPS induces hypozincaemia.
Materials andmethods:We evaluated the effects of LPS and zinc on female reproductive performance. Communi-
cation, which is impaired in autism,was tested in pups by ultrasonic vocalizations. Plasma levels of brain-derived
neurotrophic factor (BDNF) were determined because it has been considered an autism important biomarker.
Key ﬁndings: Prenatal LPS exposure reduced offspring number and treatment with zinc prevented this reduction.
Moreover, pups that were prenatally exposed to LPS spent longer periods without calling their mothers, and
posttreatment with zinc prevented this impairment induced by LPS to the same levels as controls. Prenatal LPS
also increased BDNF levels in adult offspring, and posttreatment with zinc reduced the elevation of BDNF to
the same levels as controls.
Signiﬁcance: BDNF hyperactivity was also found in several studies of autistic patients. Togetherwith our previous
studies, our model of prenatal LPS induced autistic-like behavioral, brain, and immune disturbances. This sug-
gests that it is a valid rat model of autism. Prenatal zinc prevented reproductive, communication, and BDNF im-
pairments. The present study revealed a potential beneﬁcial effect of prenatal zinc administration for the
prevention of autism with regard to the BDNF pathway.© 2015 Elsevier Inc. All rights reserved.1. Introduction
Autism is a developmental brain disorder with a higher prevalence
inmales and characterized by social deﬁcits, communication abnormal-
ities, repetitive behaviors, and sometimes changes in some blood and
brain biomarkers, such as brain-derived neurotrophic factor (BDNF)
[1,2]. One in every 100 children is diagnosed with autism [3,4]. The
risk factors seem to include genetic and perinatal environmental agents,
such as gestational zinc deﬁcit, although its exact etiology remains
unknown [5–7].
Previous investigations by our group have shown that prenatal
treatment with lipopolysaccharide (LPS; 100 μg/kg, intraperitoneally
[i.p.]), an endotoxin that mimics infection with Gram-negative bacteria,
in rats on gestational day (GD) 9.5 impaired communication and
socialization and induced repetitive/restricted behavior in male rats.School of Veterinary Medicine,
Paiva, 87, São Paulo, SP 05508-
29.However, the behavior of female ratswas not altered [8,9]. These results
suggest that our model of prenatal LPS exposure induces autism-like
effects in offspring [9]. Moreover, we observed an increase in serum
interleukin-1β (IL-1β) levels in adult offspring [10], a ﬁnding already
reported in several autistic patients [11–13]. The effects of maternal
LPS exposure on the developing fetal brain have been suggested to be
mediated by the induction of proinﬂammatory cytokines within the
maternal circulation and placenta [14–16].
No effective treatment yet exists for autism, with no consensus on
the type of medication to prescribe [17]. A few drugs have been ap-
proved by the U.S. Food and Drug Administration, but they have limited
efﬁcacy, treat only part of the symptoms, and trigger adverse effects
[18]. Therefore, the purpose of the present study was to use our rat
model of autism to test a treatment for autism. We selected zinc as
the prenatal treatment to prevent or ease the impairments induced by
LPS. Cytokines produced after LPS exposure induce metallothionein,
which sequestrates zinc and induces maternal and fetal hypozincaemia
[19]. Coyle's group reported that hypozincaemia induced by LPS leads
to teratogenesis and that zinc supplementation prevented some repro-
ductive and behavioral impairments [19,20]. Human studies have
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ment [21,22]. According to Theoharides and colleagues [7], however,
these studies are not representative because they utilized a small
number of subjects and did not have appropriate controls. Thus, evalu-
ating whether prenatal zinc can reverse the impairments found in our
rat model of autism would be interesting.
LPS and zinc can induce reproductive injuries, such as reduced litter
size [8,19]. Thus, we evaluated the effects of LPS and zinc on female re-
productive performance. Moreover, because impaired communication
between children and their mothers is a typical symptom of autism
[1], we evaluated ultrasonic vocalizations in isolated pups. We also
evaluated the plasma levels of BDNF in rat offspring prenatally exposed
to LPS and zinc because it is considered an important biomarker of
autism [23]. Recently, Ricci et al. [2] showed that autistic patients
presented elevated serum levels of BDNF, regardless of age, gender,
and severity of the disorder, compared with controls. Other studies re-
ported similar ﬁndings in plasma [24], serum [25], postmortem brain
[26], and neonatal cord blood [27] samples from autistic patients.
2. Materials and methods
2.1. Ethics statement
This study was performed in strict accordance with the recommen-
dations of the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocol was approved by the
Committee on the Ethics of Animal Experiments of the School of Veter-
inary Medicine, University of São Paulo, Brazil (permit no. 2824/2012).
All effortsweremade tominimize suffering. The experimentswere per-
formed in accordance with good laboratory practice protocols and with
quality assurance methods.
2.2. Animals
Fifteen pregnant Wistar rats between 12 and 13 weeks of age and
weighing 226–266 g were used. Rat housing, the nutritional conditions,
the determination of GD0, and the handling and care of dams were the
same as those previously described by our group [9]. The dams were
randomly divided into three groups (n = 5 per group). Two young
male offspring (postnatal day [PND] 11) from each litter were used for
the ultrasonic vocalization test (n = 10 per group). Two other adult
male offspring (PND 68–72) from each litter were used for BDNF analy-
sis (n= 8 per group, n randomly reduced according to methodological
needs) We used two different offsprings for each experiment to mini-
mize potential confounding factors associated with litter effects [28]
and because maternal isolation required for ultrasonic vocalization
test affects neurodevelopment and adult analyses [29]. All of the exper-
iments were performed between 1:30 PM and 2:00 PM tominimize the
effects of circadian rhythms.
2.3. Treatments
The LPS solutionwas described previously [9]. LPSwas administered
i.p. to pregnant dams at a dose of 100 μg/kg onGD9.5. One hour after LPS
exposure, the dams also received sterile saline (SAL; 0.9% NaCl, 0.2 ml/
100 g, subcutaneously [s.c.] in the nape of the neck) because saline
was used as the vehicle for both LPS and zinc. This group was called
LPS + SAL.
Another group received LPS (100 μg/kg on GD9.5, i.p.) and then zinc
sulfate (zinc sulfate heptahydrate, ZnSO4, Sigma, St. Louis, MO, USA, cat.
no. Z0635; 2 mg/kg in 0.9% saline, s.c., in the nape of the neck) 1 h later,
based on the ﬁndings of Coyle's group [30]. This group was called
LPS+Zn. A s.c. zinc injection induces an immediate and consistently re-
producible increase in plasma zinc that peaks at levels that are four- to
ﬁve-fold higher than normal 2 h after injection and return to normal by
12 h [31]. No evidence has been reported that these plasma zinc levelshave a detrimental effect on pregnancy outcome [20]. The recovery of
normal zinc levels 12 h after s.c. zinc injection coincides with the period
of increased levels of cytokines after LPS exposure [32,33]. The zinc so-
lution was always prepared on the day of administration.
The control group consisted of pregnant rats that received only
sterile saline on GD9.5 (0.2ml/100 g, i.p.) and an additional saline injec-
tion after 1 h (0.2 ml/100 g, s.c.). This group was called SAL + SAL.2.4. Reproductive performance
The dams were allowed to give birth and nurture their offspring
normally. Gestation length from GD0 was evaluated. The day of birth
was recorded as PND1. No handling was performed on PND1, because
it is a known fact that PND1 is a critical period of stress for the dams.
Handling on PND1 can lead to infanticide and cannibalism. On PND2,
the number of males, females and total rat pups born per litter, and
the total offspring weight were measured. Immediately after weighing,
eight offspring (four males and four females) were randomly selected
for the following studies. No cross-fostering procedure was used. Litters
with fewer than eight pups were culled. Moreover, damswere weighed
onGD9.5 andPND2 to estimate theirweight gain during pregnancy. The
pups remained with each dam until weaning (PND21). On PND21,
littermates were separated and cohoused by sex under the same
conditions as their parents.2.5. Ultrasonic vocalization
Impaired communication of the pups with their mothers, a typical
symptom of autism [1], was assessed by ultrasonic vocalization, validat-
ed for rat model of autism [9,34]. Rodent pups emit vocalizations (band
frequency of 30–50 kHz) when isolated from their mothers, and these
vocalizations are thought to solicit maternal interactions [35,36]. On
PND 11, immediately after the pups were isolated from their nests and
mothers, they were individually placed in a polypropylene cage
(30 × 20× 12 cm) and brought to a testing room at a controlled temper-
ature of 22 °C± 2 °C that was separate from the housing room. PND 11
was chosen because (1) ultrasonic vocalization is relatively temperature
independent during the second week of life compared with the ﬁrst
week, (2) high within-litter variability in call emission is observed at
this time point, and (3) substantial evidence indicates intraindividual
stability in call emission at this time point [37,38]. Ultrasonic vocaliza-
tionswere detected using Ultravox software (Noldus Information Tech-
nology, Leesburg, VA, USA) with a ﬁlter and ultrasonic microphone that
was tuned to a range centered at 40 kHz and placed 8 cm away from the
cage ﬂoor. The automatically recorded parameters during the 5-min
session included the number of vocalizations, total time of vocalizations,
meanvocalization duration,maximal vocalization duration, total silence
duration, mean silence duration interval, and maximal silence duration
interval. The durations were recorded in seconds.2.6. BDNF analysis
Trunk blood was collected from adult offspring (PND68-72) after
decapitation in conical tubes that contained ethylenediaminetetraacetic
acid. The samples were centrifuged (10 min, 1000 g, 17 °C) and plasma
was obtained. Plasma BDNF levels were determined in duplicate
using the enzyme-linked immunosorbent assay according to the
manufacturer's instructions (cat. no. G7610, Promega, Madison, WI,
USA). We evaluated free mature BDNF (i.e., non-acidiﬁed samples)
and total free BDNF (i.e., acid-treated and neutralized samples, which
is the pro-form of BDNF, together with mature BDNF). Mature BDNF is
the active form of this neurotrophin, which binds to the TrkB receptor
[39].
Table 1
Reproductive performance. Effects of prenatal LPS (100 μg/kg) and zinc (ZnSO4; 2 mg/kg)
exposure on gestational day 9.5 on reproductive parameters of dams and their rat off-
spring. SAL + SAL, prenatal saline injection and another saline injection after 1 h; LPS +
SAL, prenatal LPS injection and a saline injection after 1 h; LPS+ Zn, prenatal LPS injection
and zinc injection after 1 h (n= 5 dams/group; data are expressed as mean ± SEM).
Parameters SAL + SAL
group
LPS + SAL
group
LPS + Zn
group
Gestation length (days) 22.00 ± 0.00 22.00 ± 0.00 22.00 ± 0.00
Number of pups born 10.40 ± 0.68 7.00 ± 1.09*## 12.00 ± 0.55
Number of males born 6.20 ± 0.66 4.20 ± 0.73 5.20 ± 0.86
Number of females born 4.20 ± 1.07 2.80 ± 0.97# 6.80 ± 0.49
Dam weight (g) on GD9.5 241.6 ± 4.36 252.3 ± 5.49 246.9 ± 4.47
Dam weight gain
(g, PND2-GD9.5)
4.84 ± 1.48 2.52 ± 5.74 3.40 ± 2.78
*p b 0.05, comparedwith SAL+SAL group; #p b 0.05 and ##p b 0.01, comparedwith LPS+
Zn group (one-way ANOVA followed by Bonferroni test).
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Homogeneity was veriﬁed using Bartlett's test. Normality was veri-
ﬁed using the Kolmogorov-Smirnov test. One-way analysis of variance
(ANOVA) followed by Bonferroni's multiple comparison test was used
to compare parametric data. The results are expressed as mean ±
SEM. In all cases, the results were considered signiﬁcant at p b 0.05.3. Results
One-way ANOVA demonstrated that prenatal LPS and zinc inﬂu-
enced reproductive performance of dams (Table 1). There were differ-
ences for total number of pups born per litter (F(2/27) = 9.98, p =
0.0028). Themultiple comparisons test revealed that prenatal LPS expo-
sure (LPS + SAL) reduced offspring number compared to the control
group (SAL + SAL; p b 0.05). Treatment with zinc prevented the off-
spring number reduction of dams exposed to LPS (LPS + Zn vs.
LPS + SAL, p b 0.01) to the same levels as the control group. We also
found differences in the number of females born (F(2/27) = 5.33,
p=0.0221). Interestingly, posttreatmentwith zinc (LPS+Zn) elevated
the number of females born, compared with the LPS + SAL group
(p b 0.05), without differences between SAL + SAL and LPS + SAL
groups. Other reproductive parameters did not present statistically
signiﬁcant differences, i.e., no evidence was found that prenatal LPS
and zinc exposure did not interfered with gestation length, number of
male pups born, offspring weight, dam weight, and dam weight gain
during pregnancy (p N 0.05 for all cases).
In the ultrasonic vocalization test, the one-way ANOVA revealed sig-
niﬁcant differences in the mean silence duration interval (n = 10 per
group; F(2/27) = 4.42, p = 0.0219; Fig. 1). The multiple-comparison
test revealed that prenatal LPS exposure (LPS + SAL group) increased
the mean silence duration compared with the control group
(SAL + SAL; p b 0.05). Posttreatment with zinc reduced the meanFig. 1.Ultrasonic vocalizations of the offspring. Effects of prenatal LPS (100 μg/kg) and zinc (ZnS
offspring. SAL+ SAL, prenatal saline injection and another saline injection after 1 h; LPS+ SAL,
zinc injection after 1 h (n=10 rats/group). *p b 0.05, comparedwith SAL+ SAL group; #p b 0.0
are expressed as mean ± SEM.silence duration in rats prenatally exposed to LPS (LPS + Zn group vs.
LPS + SAL, p b 0.05) to the same levels as the control group. The one-
way ANOVA also revealed signiﬁcant differences in themaximal silence
duration interval (n= 10 per group; F(2/27) = 3.88, p= 0.0330). The
multiple-comparison test revealed that prenatal LPS exposure
(LPS + SAL group) increased the maximal silence duration compared
with the control group (SAL + SAL; p b 0.05). Posttreatment with zinc
reduced the maximal silence duration in rats prenatally exposed to
LPS (LPS + Zn group vs. LPS + SAL, p b 0.05) to the same levels as the
control group. However, no differences in the number of vocalizations
(n = 10 per group; F(2/27) = 0.06, p = 0.9365) were found among
the three groups. The total time of vocalization,mean vocalization dura-
tion,maximal vocalization duration, and total silence durationwere also
not different among the three groups (n= 10 per group; p N 0.05 in all
cases, data not shown).
As shown in Fig. 2, the one-way ANOVA revealed signiﬁcant differ-
ences in free mature BDNF (n = 8 per group; F(2/21) = 5.29, p =
0.0137). The multiple-comparison test revealed that plasma levels of
free mature BDNF increased in the LPS + SAL group compared with
the control group (SAL + SAL; p b 0.05). Posttreatment with zinc re-
duced the elevation of BDNF induced by LPS exposure (LPS + Zn
group vs. LPS + SAL, p b 0.05) to the same levels as the control group.
However, no differences in total free BDNF levels were found among
the three groups (n= 8 per group; F(2/21) = 2.48, p= 0.1080).4. Discussion
Prenatal infection/inﬂammation onGD 9.5 falls within a critical peri-
od for brain organogenesis. Infections associated with immunological
events during the early/middle fetal stages (e.g., GD 8–10 in rats and
mice) might have a stronger impact on neurodevelopment than
infections that occur during late-stage pregnancy. Maternal immune
activation during early/middle pregnancymay interfere with cell prolif-
eration, differentiation,migration, target selection, and synapsematura-
tion, eventually leading to multiple brain and behavioral abnormalities
in adulthood [40–43]. Previous data from our group corroborated that
GD 9.5 is a critical period. We showed that prenatal treatment with
LPS onGD9.5 in rats induced short- and long-term reproductive, behav-
ioral, and neuroimmune impairments in the offspring [8–10,44–46].
Prenatal LPS exposure impaired the reproductive performance of
rats. Prenatal LPS reduced the number of offspring born compared to
the control group. Our previous studies have already shown a toxic ef-
fect of LPS in the reproductive performance, including injuries in the
placental tissue and higher post-implantation loss [10]. Prenatal LPS
can also induce spontaneous abortion, embryo resorption and intrauter-
ine mortality [47,48].
Posttreatment with zinc prevented the reduction of the offspring
number of dams exposed to LPS, restoring reproductive success similar
to that found in controls. Accordingly, a study conducted with pregnant
women in New Jersey have shown that pregnancy with low zinc dietO4; 2mg/kg) exposure on gestational day 9.5 on ultrasonic vocalizations in infantmale rat
prenatal LPS injection and a saline injection after 1 h; LPS+ Zn, prenatal LPS injection and
5, comparedwith LPS+ Zn group (one-way ANOVA followed by Bonferroni test). The data
Fig. 2. BDNF levels of the offspring. Effects of prenatal LPS (100 μg/kg) and zinc (ZnSO4; 2mg/kg) exposure on gestational day 9.5 on plasma freemature and total free BDNF levels in adult
male rat offspring. SAL + SAL, prenatal saline injection and another saline injection after 1 h; LPS + SAL, prenatal LPS injection and a saline injection after 1 h; LPS + Zn, prenatal LPS in-
jection and zinc injection after 1 h (n=8 rats/group. *p b 0.05, comparedwith SAL+ SAL group; #p b 0.05, comparedwith LPS+ Zn group (one-way ANOVA followed by Bonferroni test).
The data are expressed as mean ± SEM.
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with zinc [49]. Proper transfer of zinc to the fetus during pregnancy is
dependent on maintaining the normal concentration maternal zinc; in
other words, there are no speciﬁc sites of zinc stock to compensate the
momentary deﬁciency in maternal zinc [19,50]. Smoking, alcohol
abuse and stressful responses to trauma and infections can reduce
maternal concentration of zinc, being zinc supplementation prudent
for women during pregnancy [50]. The oral administration of zinc to
volunteers reduced reproductive impairments both in mother and
fetus; zinc was well tolerated and accepted by patients, without
inducing adverse effects [51].
In other mammals, the process seems to be similar. Coyle and
colleagues demonstrated that LPS on GD8 induced a 40% decrease of
plasma levels of zinc in mice. LPS induced teratogenesis, and zinc s.c.
injection or dietary zinc supplementation of dams prevented these
injuries [19,20,52].
According to Coyle et al. [19], control (saline) group that received
zinc supplementation presented no reproductive performance impair-
ments in maternal weight, number of litters, pup weight, and resorp-
tions, although the litter size was slightly reduced compared with the
control group. Thus, considering these reproductive results, we would
not suggest prenatal zinc administration during gestationwithout infec-
tious or inﬂammatory processes.
The fact that zinc treatment increased the number of females born
compared to the data of the LPS group was extensively searched in
the literature to verify whether this sexually dimorphic effect has
been described, and if there is some explanation for this phenomenon.
We did not ﬁnd any similar report of sexually dimorphic effects induced
by zinc. Thus, further studies are needed to verify the reproducibility of
these data and elucidate the mechanisms involved in the dimorphism
induced by prenatal zinc.
Pups that were prenatally exposed to LPS spent longer periods
without emitting 40 kHz vocalizations to their mothers (i.e., prenatal
LPS reduced vocal solicitations by infant offspring to their mothers).
The 40 kHz ultrasonic vocalization frequency is used by pups when
they are separated from their mothers to request the presence of the
mother [53]. The present results showed that prenatal LPS exposure
impaired communication in male pups. Impaired communication
between children and their mothers is one of the main symptoms of
autism [1]. The test of 40 kHz ultrasonic vocalization is validated for
rat models of autism [9,34]. Thus, prenatal LPS exposure induced
autistic-like behavior in rats.
Prenatal zinc administration prevented the communication impair-
ment induced by LPS exposure to the same levels as controls. Therefore,
prenatal zinc prevented autistic-like behavior in rats.
According to Caulﬁeld et al. [54], prenatal zinc supplementation
without inﬂammatory processes does not inﬂuence cognitive and social
skills, as well as behavioral development. Thus, it seems that prenatal
zinc induces behavioral changes only after an inﬂammatory process
(e.g., induced by LPS).BDNF is a small protein found throughout central nervous system,
and peripheral blood. It is a member of a family of secreted proteins
known as neurotrophins. It regulates neuronal survival, morphology,
development, and function and plays a critical role in synaptogenesis
and synaptic plasticity [55]. We also found that prenatal LPS exposure
elevated BDNF levels in rats similarly to autistic patients [2,24,25]. To
our knowledge, the present study that found that prenatal LPS exposure
elevated BDNF levels is the ﬁrst rodent model of autism to reveal this
similarity to autistic patients. In fact, early BDNF hyperactivity may
play an etiological role in autism early in life. This hypothesis is support-
ed by previous studies that reported increased blood and brain tissue
BDNF levels in autism compared with normal controls [56].
Together with our previous studies, our model induced impaired
communication and socialization, induced repetitive/restricted behav-
ior, increased serum IL-1β levels [8–10], and increased plasma BDNF
levels in rats. Therefore, prenatal LPS exposure induced autism-like
effects in offspring, revealing that it is a robust rat model of autism.
Tsai [56] hypothesized a correlation between autism and BDNF
levels. Increased BDNF levels in autistic patients may reﬂect a regional
compensatory mechanism or develop as an intrinsic component of the
disease process. In fact, brain growth is abnormal in autism, indicated
by early brain overgrowth. Because BDNF plays a key role in regulating
neuronal survival [55], early BDNF hyperactivity could result in the
overgrowth of brain tissue [56].
We cannot forget to mention that although the majority of studies
involving autism and BDNF reveal high levels of BDNF in autistic pa-
tients, regardless of age, gender, severity of the disorder, and type of
sample [2,24–27,56], the results are sometimes contradictory. For ex-
ample, there are data showing thatmean levels of BDNF are signiﬁcantly
lower in autistic children 0–9 years old, indicating a delayed BDNF in-
crease with development and not an increase in BDNF levels [57].
Both human and rat studies have demonstrated that BDNF levels in
the blood reﬂect BDNF levels in the brain [57,58]. Thus, our data suggest
a disturbance of brain BDNF. Incidentally, in addition to autistic-like be-
havior, we previously found that ourmodel of prenatal LPS also resulted
in striatal dopaminergic impairments in adult offspring, including re-
duced levels of tyrosine hydroxylase, dopamine, and its metabolites
[9,44]. BDNF is involved in the survival and differentiation of dopami-
nergic neurons in the developing brain [2]. For example, repeated
administration of stimulant drugs can cause permanent changes in
dopamine levels and both transient and permanent alterations in
BDNF and tyrosine hydroxylase expression, inducing long-term
neuroadaptations of both BDNF and dopamine [59,60]. BDNF is robustly
expressed in the mesolimbic pathway. The mesolimbic pathway is the
anatomical substrate for intricate interactions between dopamine and
BDNF [61]. We believe that the striatal dopaminergic and BDNF distur-
bances found after prenatal LPS exposure may be correlated, but this
possibility requires further study.
Interestingly, we found a disturbance in freemature BDNF levels and
not total free BDNF levels, which includes the BDNF precursor pro-
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be abnormal in patients with autism [26,62]. Speciﬁcally, mature
BDNF promotes spine formation, neuronal survival, and long-term
potentiation [63,64].
In addition to demonstrating that the plasma levels of free mature
BDNF were increased after prenatal LPS exposure, we also found that
posttreatmentwith zinc reduced the elevation induced by LPS exposure
to the same levels as the control group. Zinc is oneof themost important
trace elements in mammals, and it is required for many physiological
processes, such as cell proliferation and differentiation, growth and de-
velopment, and the regulation of enzymatic activity [65]. Some studies
in the literature show that zinc administration may induce BDNF ex-
pression [66]. Yang and colleagues [67] showed that zinc supplementa-
tion reduced BDNF levels in the hippocampus by reducing BDNF-TrkB
neurotrophic signaling. In fact, zinc was previously proposed to be a po-
tential agent for the treatment of Rett syndrome [68], which is included
in autism spectrum disorder [1]. However, we emphasize that the
present study is likely the ﬁrst to investigate zinc for the prevention/
treatment of autism with regard to the BDNF pathway.
Yu et al. [69] demonstrated that pups of pregnant rats thatwere oral-
ly supplemented with zinc presented a decrease in hippocampal BDNF
levels compared with control animals. Thus, considering the BDNF im-
pairments induced by zinc, we would not suggest prenatal zinc admin-
istration during gestationwithout infectious or inﬂammatory processes.
The present ﬁndings revealed a potential beneﬁcial effect of prenatal
zinc administration for the prevention of autism. Importantly, epidemi-
ological studies have correlated infections during pregnancy with a
higher incidence of children diagnosed with autism [70]. Thus, by ex-
trapolating to humans, we suggest that when the ﬁrst signs of sickness
behavior associatedwith an infection in pregnantwomen are perceived,
such as those induced by LPS, zinc could be administered to prevent the
development of autism in newborns.
5. Conclusions
In conclusion, prenatal LPS exposure on GD 9.5 impaired communi-
cation and increased plasmaBDNF levels in rat offspring. This communi-
cation impairment and BDNF hyperactivity was similar to many studies
of autistic patients [1,2,24,25,27,71]. Together with our previous studies
[8,9] ourmodel induced autistic-like behavioral, brain, and immune dis-
turbances, demonstrating that it is a robust ratmodel of autism.We also
found that posttreatment with zinc prevented the communication im-
pairment and BDNF hyperactivity induced by LPS exposure. Thus, to
our knowledge, this is the ﬁrst study to reveal a potential beneﬁcial
effect of prenatal zinc administration for the prevention/treatment of
autism with regard to the BDNF pathway. The reproductive parameters
study corroborates the toxic effects of LPS during gestation, and theben-
eﬁcial preventive effect of zinc in the reproduction. The present ﬁndings
may contribute to a better understanding and prevention/treatment of
autism and associated diseases.
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